Roche has introduced its Axelios 1 platform, a next-generation sequencing system that is available for research use and powered by its SBX technology.

HB Fuller says the AMS acquisition would expand its TAM by $15bn, while bringing in around $300m in extra annual revenue.

Tissium will now bring COAPTIUM CONNECT, the first atraumatic peripheral nerve repair surgical system, to patients in the US.

Quest Diagnostics has received approval from the NYSDOH CLEP for its Haystack MRD test, expanding its use to cancer patients throughout the US.

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

Researchers from the UF Health Cancer Institute in the US are developing a rapid, non-invasive urine test aimed at diagnosing prostate cancer and distinguishing it from other prostate-related ...

CereVasc has concluded patient enrolment in its STRIDE study, assessing the safety and effectiveness of the eShunt system for NPH.

The new initiative is intended to improve the global oversight of medical devices, AI, and innovative medicines and to streamline knowledge sharing efforts.

This authorisation will expand the B-Right AI platform’s use to Europe, as BrightHeart continues to roll the technology out across the US.

Imperative Care has reported results from a post-hoc analysis of the SYMPHONY-PE Trial, assessing the role of early mechanical thrombectomy in patients diagnosed with intermediate-risk PE.

Chemomouthpiece has formed a partnership with Zeal Specialty Pharmacy to expand access to its Chemo Mouthpiece oral cooling device in the US.

AngioDynamics has received approval from the FDA for an IDE application to begin the RELIEF clinical trial of NanoKnife.